Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
NVIDIA
NVDA
|
$2.08B |
| 2 |
Microsoft
MSFT
|
$699M |
| 3 |
Exxon Mobil
XOM
|
$614M |
| 4 |
Apple
AAPL
|
$587M |
| 5 |
UnitedHealth
UNH
|
$448M |
Top Sells
| 1 |
Broadcom
AVGO
|
$1.1B |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
$477M |
| 3 |
GE Aerospace
GE
|
$375M |
| 4 |
AEL
American Equity Investment Life Holding Company
AEL
|
$271M |
| 5 |
Applied Materials
AMAT
|
$209M |
Sector Composition
| 1 | Technology | 20.72% |
| 2 | Financials | 16.94% |
| 3 | Industrials | 12.29% |
| 4 | Consumer Discretionary | 10.5% |
| 5 | Healthcare | 10% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3301
SOPHiA GENETICS
SOPH
$220M
| $56.8K | ﹤0.01% |
12,354
| – | – |
|
3302
RAVE Restaurant Group
RAVE
$47.9M
| $56K | ﹤0.01% |
28,288
-5,715
| -17% | -$11.3K |
|
3303
Tempest Therapeutics
TPST
$47.6M
| $54.9K | ﹤0.01% |
+1,930
| New | +$54.9K |
|
|
PMD
3304
DELISTED
Psychemedics Corporation
PMD
| $54.9K | ﹤0.01% |
22,688
-13,429
| -37% | -$32.5K |
|
3305
ReWalk Robotics
LFWD
$8.63M
| $54.3K | ﹤0.01% |
+13,548
| New | +$54.3K |
|
3306
AN2 Therapeutics
ANTX
$33.1M
| $54.1K | ﹤0.01% |
25,150
-12,965
| -34% | -$27.9K |
|
3307
One Stop Systems
OSS
$124M
| $53.6K | ﹤0.01% |
22,257
| – | – |
|
3308
IRIDEX
IRIX
$23.6M
| $52.8K | ﹤0.01% |
24,438
-23,889
| -49% | -$51.6K |
|
3309
BuzzFeed
BZFD
$69.6M
| $52.6K | ﹤0.01% |
+19,064
| New | +$52.6K |
|
3310
Milestone Pharmaceuticals
MIST
$151M
| $52.4K | ﹤0.01% |
39,450
| – | – |
|
|
WHWK
3311
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.8M
| $52.2K | ﹤0.01% |
35,656
+61
| +0.2% | +$89 |
|
3312
Sypris Solutions
SYPR
$49.1M
| $52K | ﹤0.01% |
27,095
-9,600
| -26% | -$18.4K |
|
|
BMTX
3313
DELISTED
BM Technologies, Inc.
BMTX
| $52K | ﹤0.01% |
23,106
-14,016
| -38% | -$31.5K |
|
|
KLRS
3314
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86.2M
| $50.8K | ﹤0.01% |
3,033
| – | – |
|
|
VXRT
3315
DELISTED
Vaxart
VXRT
| $50.4K | ﹤0.01% |
75,491
-2,332
| -3% | -$1.56K |
|
3316
PharmaCyte Biotech
PMCB
$6.55M
| $50.2K | ﹤0.01% |
25,596
+1,033
| +4% | +$2.03K |
|
3317
DiaMedica Therapeutics
DMAC
$310M
| $50K | ﹤0.01% |
16,959
| – | – |
|
3318
Edesa Biotech
EDSA
$17.6M
| $48.7K | ﹤0.01% |
11,333
| – | – |
|
3319
MEI Pharma
MEIP
$136M
| $48.2K | ﹤0.01% |
16,572
-390
| -2% | -$1.14K |
|
|
IAUX
3320
i-80 Gold Corp
IAUX
$665M
| $48.1K | ﹤0.01% |
44,547
| – | – |
|
3321
Ring Energy
REI
$204M
| $47K | ﹤0.01% |
27,818
| – | – |
|
3322
Intellicheck
IDN
$107M
| $46.9K | ﹤0.01% |
+13,703
| New | +$46.9K |
|
3323
Aprea Therapeutics
APRE
$9.2M
| $45.1K | ﹤0.01% |
+11,071
| New | +$45.1K |
|
3324
Repare Therapeutics
RPTX
$73M
| $43.8K | ﹤0.01% |
13,265
-27,504
| -67% | -$90.8K |
|
3325
Cardiff Oncology
CRDF
$144M
| $42.4K | ﹤0.01% |
19,098
+4,892
| +34% | +$10.9K |
|